| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe6a152ab369ec0c2c593941a1ee036 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2016-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688aad432fde9f8438312a2a85a27bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7e68c036c9d93bf6005005592483ff6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a292ddd03df45290316de9269fb0d208 |
| publicationDate |
2016-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016216510-A |
| titleOfInvention |
Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
| abstract |
The present invention provides compositions and methods for achieving sustained therapeutic drug concentrations in a subject. Described herein are compounds and methods for achieving sustained therapeutic effects of small molecule anticancer agents upon in vivo administration. Provided herein are methods for achieving a metronomic dosing profile in vivo upon a single administration of a topoisomerase inhibitor prodrug. The method comprises administering a prodrug of a topoisomerase inhibitor, wherein the topoisomerase inhibitor is releasably linked to a polyethylene glycol moiety to a mammalian subject (such as a human), thereby providing a single dose. A plasma concentration of the topoisomerase inhibitor or metabolite thereof is maintained above the detection level for at least 7 days after administration. [Selection] Figure 1 |
| priorityDate |
2008-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |